

Sent via email: [REDACTED] ; [REDACTED]

[REDACTED], Chair of Trustees
[REDACTED], Chief Executive
Batten Disease Family Association
209-211 City Road
London
EC1V 1JN

3 April 2019

Dear [REDACTED] and [REDACTED]

Final Evaluation Determination: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2

Thank you for your reply to my letter of 18 March 2019. I stated in my letter to you that I was not minded to agree that the Batten Disease Family Association's appeal points raised were valid and I invited you to comment on my initial scrutiny letter. Based on your response, I have taken the decision that the Institute will not be conducting an appeal hearing in relation to the Highly Specialised Technologies Evaluation Committee's final determination in this matter.

Yours sincerely

Mr Tim Irish
Vice Chair of NICE